Briefing
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma
FDA-aligned meta-analysis of 8 newly diagnosed MM randomized trials (n=4,907). Trial-level association between 12-month MRD negativity and PFS: R²_WLSiv 0.67 (95% CI 0.43-0.91) and R²_copula 0.84 (0.64 to >0.99). Individual-level global OR for 12-month MRD negativity and PFS was 4.02 (95% CI 2.57-5.46) in NDMM and 7.67 (4.24-11.10) in 4 relapsed/refractory studies. Supported the case that a treatment effect on MRD is reasonably likely to predict a treatment effect on PFS. One of the two meta-analyses presented at the April 2024 ODAC.
- Design: paper
- n: 4907
- Assay: MRD negativity at 12±3 months (trial-level and individual-level association with PFS)